Explanatory Note:
This joint statement on Schedule 13D/A is filed with respect to the common stock, par value $0.001 per share (“Common Stock”), of Molecular Templates, Inc., a Delaware corporation (the “Issuer”).
This Amendment No. 6 to Schedule 13D (“Amendment No. 6”) amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission (the “Commission”) on September 18, 2017, as amended by Amendment No. 1 filed with the Commission on September 26, 2018 (“Amendment No. 1”), Amendment No. 2 filed with the Commission on December 5, 2019 (“Amendment No. 2”), Amendment No. 3 filed with the Commission on June 5, 2020 (“Amendment No. 3”), Amendment No. 4 filed with the Commission on February 14, 2023 (“Amendment No. 4”) and Amendment No. 5, filed with the Commission on October 24, 2023 (“Amendment No. 5” and together with Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5, the “Original Schedule 13D”). This Amendment No. 6 is being filed to update the aggregate percentage of the Issuer’s Common Stock owned by the Reporting Persons due to dilution caused by, among other things, the Issuer’s sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D and not in connection with a disposition of any shares by the Reporting Persons. Such dilution resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Original Schedule 13D is hereby amended to add the following language:
(a) and (b) See Items 7-11 of the cover pages of this Amendment and Item 2 above.
(e) On April 25, 2024, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock.